Carlsquare Equity Research has updated its view on Biosergen following the progress made in India and the report for the second quarter.

Read the full update here.

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team has extensive experience about the stock
environment and several business sectors. The team produces company research reports,
independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. Read more

Contacts

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20
 
NIKLAS ELMHAMMER
Senior Equity Analyst
niklas.elmhammer@carlsquare.com
+46 (0)70 898 39 59

Attachments

Research update Biosergen: First patient treated in phase Ib study a success